Table 2.

Efficacy of MARV vaccines in NHPs

Vaccine	Challenge virus	Vaccine doses	Time to challenge (d)a	Survival (%)	Ref.
Whole virus
inact. MARV	MARV Popp	2	21	50	[8]
VLPs
VLPs + RIBI	MARV Musoke, Ci67, RAVV	3	28	100	[19]
mVLPs + adjuvant	MARV Musoke	3	28	100	[20]
DNA
MARV GP	MARV Musoke	3	28	67	[32]
MARV GP	MARV Angola	4	42	100	[33]
MARV GP, RAVV GP, EBOV GP, SUDV GP	MARV Musoke	3	56	100	[31]
DNA + rec. Adenovirus
DNA MARV GP, rAD5-MARV GP	MARV Angola	4	21	100	[33]
Replicon
VEEV-MARV GP, VEEV-MARV NP, both	MARV Musoke	3	35	67–100	[25]
rec. Adenovirus
CAdVax-panFilo	MARV Musoke, Ci67	2	42, 112	100	[40]
rAD5-MARV GP	MARV Angola	1	28	100	[33]
rec. Vesicular stomatitis virus
VSV-MARV	MARV Musoke, Popp	1	28, 113	100	[59]
VSV-MARV	MARV Musoke, Angola, RAVV	1	28	100	[79]
VSV-MARV	MARV Angola	1	28	100	[77]
VSV-EBOV, VSV-SUDV, VSV-MARV	MARV Musoke	1	28, 59	100	[60]
VSV-MARV	MARV Musoke	1	407	100	[80]

^aTime until challenge after vaccination was completed